NurExone Biologic Inc. Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Core Insights - NurExone Biologic Inc. reported its financial results for Q3 2025, highlighting significant advancements in its exosome-based therapies for central nervous system injuries [1][24] Financial Performance - Net R&D expenses for Q3 2025 were US$0.70 million, an increase from US$0.50 million in Q3 2024, attributed to higher headcount and service provider costs [19] - G&A expenses decreased slightly to US$0.76 million in Q3 2025 from US$0.78 million in Q3 2024, mainly due to lower service provider costs [20] - The net loss for Q3 2025 was US$1.47 million, compared to US$1.25 million in Q3 2024 [21] Corporate Developments - The company accelerated the expiry of 8.2 million warrants, raising approximately C$3.2 million to support corporate needs [3] - NurExone announced reproducible dose-dependent vision recovery in a glaucoma model, reinforcing the potential of its lead candidate, ExoPTEN [4] - The company secured patent grants in the U.S. and Israel for its exosome production process, enhancing its intellectual property position [11][12] Scientific Recognition - NurExone was named a finalist in two prestigious international award programs, highlighting its innovative approach in regenerative medicine [6] - The company enhanced its scientific visibility through presentations at leading conferences, including the Precision EV Forum 2025 [5] Upcoming Events - An investor webinar titled "Investing in the Future of Exosome Therapeutics" is scheduled for December 10, 2025, to discuss recent achievements and strategic priorities [7] Capital Raising Activities - The company raised C$1.4 million through private placements in August and September 2025, which will be used for working capital and clinical development [8][9][10] Manufacturing Expansion - Plans for a U.S. commercial exosome production facility in Indianapolis were announced, supported by an incentive offer of up to US$0.26 million [13] - NurExone joined the ARMI/BioFabUSA BioFab Startup Lab to strengthen its U.S. biomanufacturing presence [15]